PROTHENA CORP PLC (PRTA) Stock Analyst Ratings
USA - NASDAQ:PRTA - IE00B91XRN20 - Common Stock
10.36 USD
+0.11 (+1.07%)
10.36 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 75% to PRTA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 16.83. This target is 62.45% above the current price.
PRTA was analyzed by 13 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about PRTA.
In the previous month the buy percentage consensus was at a similar level.
PRTA was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-07 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-28 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-02 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-28 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-08-05 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-05 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-08-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-20 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2025-05-28 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2025-05-27 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-27 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-27 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2025-05-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-26 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-21 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-21 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-21 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-02-21 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2025-02-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-07 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-12-20 | Chardan Capital | Initiate | Buy |
| 2024-12-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
PROTHENA CORP PLC / PRTA FAQ
What is the price target for PRTA stock?
13 analysts have analysed PRTA and the average price target is 16.83 USD. This implies a price increase of 62.45% is expected in the next year compared to the current price of 10.36.
How do analysts rate PROTHENA CORP PLC (PRTA)?
The consensus rating for PROTHENA CORP PLC (PRTA) is 75.3846 / 100 . This indicates that analysts generally have a positive outlook on the stock.